Nature Reviews Clinical Oncology
Издатель: Springer Nature · 8 статей
-
From the ESMO Congress 2026
Nature Reviews Clinical Oncology, Published online: 18 November 2026; doi:10.1038/s41571-026-01234-y From the ESMO Congress 2026
-
Cancer vaccines in the era of immunotherapy: from antigen delivery to immune ecosystem engineering
Nature Reviews Clinical Oncology, Published online: 17 November 2026; doi:10.1038/s41571-026-01224-0 Therapeutic cancer vaccines reliably induce antitumour immune responses but evidence of translation into clinical benefit has largely...
-
Global landscape of early-onset breast cancer: from understanding risk to precision prevention and cancer interception
Nature Reviews Clinical Oncology, Published online: 17 November 2026; doi:10.1038/s41571-026-01222-2 The rising incidence and persistent disparities that characterize early-onset breast cancers (those diagnosed before 50 years of age)...
-
T cell redirection in high-risk smouldering multiple myeloma: can deep responses prevent progression to multiple myeloma?
Nature Reviews Clinical Oncology, Published online: 10 November 2026; doi:10.1038/s41571-026-01230-2 The randomized phase II ImmunoPRISM trial has shown encouraging efficacy of the B cell maturation antigen-targeted bispecific T cell...
-
Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC
Nature Reviews Clinical Oncology, Published online: 09 November 2026; doi:10.1038/s41571-026-01233-z Divarasib outperforms first-generation KRAS-G12C inhibitors in NSCLC
-
Risvutatug rezetecan has promising efficacy in osteosarcoma
Nature Reviews Clinical Oncology, Published online: 09 November 2026; doi:10.1038/s41571-026-01228-w Risvutatug rezetecan has promising efficacy in osteosarcoma
-
Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC
Nature Reviews Clinical Oncology, Published online: 06 November 2026; doi:10.1038/s41571-026-01232-0 Sacituzumab tirumotecan–pembrolizumab has efficacy in PD-L1-negative NSCLC
-
Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC
Nature Reviews Clinical Oncology, Published online: 06 November 2026; doi:10.1038/s41571-026-01227-x Unprecedented OS with the addition of tarlatamab to first-line maintenance therapy for ES-SCLC